DEVELOPING CLINICAL TRIALS INFRASTRUCTURE
|
|
- Laurence Rich
- 5 years ago
- Views:
Transcription
1 DEVELOPING CLINICAL TRIALS INFRASTRUCTURE SESSION IV of IOM Workshop: Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020 PAUL EISENBERG PETRA KAUFMANN JANET WOODCOCK Senior Vice President Director, Office of Clinical Research Director, Center for Drug Global Regulatory Affairs & Safety Natl. Inst. Neurol. Dis.&Stroke Evaluation and Research Amgen Inc. NINDS/NIH US Food & Drug Administration November 7-8, 2011 Washington, DC
2 Outline Petra Kaufmann MD I. Introduction Infrastructure to improve trial implementation Paul Eisenberg MD II. Participant recruitment II. Regulatory process Jane Woodcock PhD III. Opportunities
3 Potential elements of a trials infrastructure Investigator Recruitment Contractual agreements Participant recruitment plan Coordination of investigators (US and globally) Quality control systems Data collection, management, and analysis Data standards Communication of results Registration of trials and results with ct.gov
4 Good Clinical Practice (GCP) Informed consent (ICF) Ethical review (Institutional Review Board, IRB) Protocol development Human research participant protection Privacy Investigator training and qualification Adverse event (AE) reporting
5 Issues to be addressed: What would constitute an optimal clinical trials infrastructure in the U.S.? How would such an infrastructure address the problems stated above? Should infrastructure solutions be universal, tailored to specific research settings, or integrated through common standards? What would be required to develop a clinical trials infrastructure? What is achievable in the near- versus longterm?
6 I. TRIAL IMPLEMENTATION Areas that infrastructure could address: Investigator Training Standardized core content CME Standardized online training and certification Central certification Online system for sponsors and institutions to centrally verify qualifications
7 Investigator Recruitment IT solutions for matching investigators to sponsors Central information on Expertise Capacity Resources Patient access Track record? Patient access data could be drawn in deidentified manner for clinical databases
8 Potential Approaches: Performance sites Non-traditional contributors: Clinicians with limited research experience Private practice settings Non-academic hospitals Benefits: Trials are conducted in relevant settings Results may be more broadly applicable Obtain data that are needed to implement the US Healthcare Reform Act
9 Investigator networks Selecting primary care or specialty care providers based on affiliation with academic center or geographic proximity Through a web-based approach
10 What would be required? Disease specific networks that include community practitioners and use standardized data collection hub and spoke virtual coordinator Networks that focus on a group of diseases or particular population Flexible networks with broad scope Support from multiple stakeholders, tax?
11 Web-based approach to trial development Clinical concept and question posted online Investigators and sponsors could propose trials Patients and other stakeholders could pose question to be answered through trials Engaging patients in developing key research questions could help facilitate downstream recruitment Online system would serve many stakeholders partnership?
12 Infrastructure to engage potential trial participants Make research discussion part of the clinical encounter EMR notification to physicians Document similar to advanced directive Part of hospital admission or clinic check in Clinical trial card (like organ donor card)
13 Novel approach to trial coordination Expanding support to non-traditional centers Flexible infrastructure to provide coordination and administrative help Web-supported beyond data management Built-in central data-driven monitoring Integrated with training and certification elements for investigators
14 Potential approaches: Technology Web-based trial Trial in a box Mobile technology Social media (e.g. for recruitment)
15 II. Regulatory Issues Impact of regulatory processes and policies: Efficiency, cost and strategy for clinical trials IND vs other processes for approval of early phase studies Clinical trial notification vs applications Clinical trial material and manufacturing issues Companion diagnostics ( personalized medicine ) Investigative product co-development Devices Adverse event notification processes GCP inspection expectations
16 Clinical Trial Implementation Issues Institutional issues: Lack of consistent trial contract expectations Variable criteria for defining appropriate clinical trial policies and processes Variability in Informed Consent expectations Ethical Review Board (ERB) timing and processes Management of privacy requirements Variability in institutional infrastructure to support clinical trials Challenges in working across therapeutic areas
17 IRB and Protocol Opportunities Central IRB s Enhances protection of human subjects Cede initial review to central IRB Short period for local comments Online protocol tools Authoring Amendments Communication Continued development of e-tools for AE reporting, integration of EMR, etc.
18 Regulatory Opportunities Regulatory agency cooperation and harmonization opportunities: Development of harmonized clinical trial application modules (e.g. common technical document) Cooperation in assessment of technical components (e.g. clinical trial material, diagnostic tests, devices) Flexible processes for phase and/or type of trial Standardized nomenclature with respect to key regulatory definitions International identification scheme for clinical trials Development of a global clinical trial database
19 Safety-Related Regulatory Opportunities Global harmonization of regulatory requirements for AE reporting to agencies, investigators, and IRBs Adoption of DSUR (Develoment Safety Update Report) Uniform approach to assessment and reporting of safety issues Reduce AE reporting to investigators and IRBs by focusing on significant new information Online management of ICF
20 Disruptive Regulatory Approaches Global clinical trial database would allow regulators to leverage other regulatory decisions Further development of regulator cooperation in evaluating clinical trials would be facilitated by more explicit involvement of stakeholders Development of mechanisms to transparently share pre-approval data with stakeholders
21 Communication of Clinical Trials Clinicaltrials.gov Benefits from requirement for accurate and current information Nonetheless data may be incomplete or insufficient Not designed for patients or public Is there value in fit for purpose alternatives for available trials and results (i.e. consumer friendly, searchable, linked to consumer and professional sites)
22 e-based Medical Research Model Principle of social network and crowd sourcing Develop an e-based market for medical research (trusted owner ) Stakeholders e.g. investigators, scientists, patients, investors, clinical trial coordinators, pharmacists, others? Utilize a certification process for participation Include participation opt-in mechanism Socialize trials (interventional and observational), concepts, protocols, clinical trial networks, etc.
23 III. Opportunities
24 Issues to be addressed: What would constitute an optimal clinical trials infrastructure in the U.S.? How would such an infrastructure address the problems stated above? Should infrastructure solutions be universal, tailored to specific research settings, or integrated through common standards? What would be required to develop a clinical trials infrastructure? What is achievable in the near- versus long-term?
International Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationRegulatory issues for academicled multinational trials in Asia: Who takes responsibility?
CVCT Asia Workshop, 15 July 2018 Regulatory issues for academicled multinational trials in Asia: Who takes responsibility? Commentary : Kaori Shinagawa, MD, PhD Senior Scientist for Clinical Medicine Pharmaceuticals
More informationHow did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949
ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org May 31, 2012 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville, MD
More informationCDER Perspective: Good Clinical Practice
CDER Perspective: Good Clinical Practice Sensible Guidelines Symposium, 25 May 2012 Ann Meeker-O Connell FDA, CDER, Office of Compliance Office of Scientific Investigations The views presented in this
More informationA SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN
A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN Version 1 - June 2017 A Short Guide For CT Application 1 2 A Short Guide For CT Application DEFINITIONS Clinical
More informationPragmatic Clinical Trials for Regulatory Decisions
Pragmatic Clinical Trials for Regulatory Decisions Jacqueline Corrigan-Curay, MD JD Office of Medical Policy Center for Drug Evaluation and Research FDA May 16, 2018 Pragmatic Clinical Trials Pragmatic
More informationAustralia: A Dynamic Environment for Conducting Clinical Trials
Australia: A Dynamic Environment for Conducting Clinical Trials MTPConnect s goal is to accelerate the growth of Australia s MTP sector Industry Associations Governments Universities Researchers Investors
More informationGlobal Clinical Trials in Korea
Global Clinical Trials in Korea In-Sook Park Department of Drug Evaluation Korea Food & Drug Administration Contents Regulatory changes relevant to Clinical Trials in Korea Current Status of Clinical Trials
More informationCreation of a pan-european Paediatric Clinical Trials Network. Heidrun Hildebrand (Bayer) & William Treem (Janssen),
Creation of a pan-european Paediatric Clinical Trials Network Heidrun Hildebrand (Bayer) & William Treem (Janssen), 19.12.2016 IMI webinar Need for public-private collaboration Due to European Regulation,
More informationCollege of American Pathologists. Statement to the National Institutes of Health on the proposed Genetic Testing Registry.
College of American Pathologists Statement to the National Institutes of Health on the proposed Genetic Testing Registry July 12, 2010 College of American Pathologists 1350 I Street, NW, Suite 590 Washington,
More informationNew Regulation in Japan and Future Direction of PMDA. Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)
New Regulation in Japan and Future Direction of PMDA Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following
More informationLouise Brook Clinical Trials Quality Monitor. Date
Details: Author: Louise Brook Clinical Trials Quality Monitor SOP Pages: 12 Version No. of replaced SOP: Effective date of replaced SOP: NA NA Approval: Version No: of the SOP being approved. Name of person
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland Question 1: What laws or regulations apply to an application for conducting a clinical
More informationConducted Under an IND to Support a
Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.
More informationRecommendations for Strengthening the Investigator Site Community
Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials
More informationAudit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
More informationImplications for Investigator Initiated Trials (IITs)- Risk Based Approaches in Managing Clinical Trials
Implications for Investigator Initiated Trials (IITs)- Risk Based Approaches in Managing Clinical Trials Lisa Marie Saldanha Senior Director & Head Academic Research & Delivery Solutions Real World Insights
More informationCourse Title ID Duration Basic Premium. Biological Evaluation of Medical Devices: A Risk-Based Approach N mins
Pre-Clinical Basic Level : CMDA Certified Medical Device Associate Biological Evaluation of Medical Devices: A Risk-Based Approach N134 63 mins 186.00 144.00 Introduction to Process Validation N135 75
More informationRisk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight
Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight Lisa Marie Saldanha Senior Director & Head of Operations Real World Insights Asia Singapore Research & Ethics Conference
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down
Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 1. BACKGROUND 17. Study Close Down According to ICH Good Clinical Practice (GCP)
More informationWebinar Series Physician Relations. Referral Development. Advancing the Physician Relations Program Structure
Webinar Series 2017 Physician Relations Referral Development Advancing the Physician Relations Program Structure Webinar Series 2017 Physician Relations Today s Agenda You will Learn: What are the right
More informationPHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008
PHARMA CONGRESS October 28, 2008 Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments Beverly H. Lorell, MD Senior Medical & Policy Advisor King & Spalding LLP Assessing
More informationQuality Measurement to Enhance Care
Quality Measurement to Enhance Care National Association of Medicaid Directors Fall Conference November 12, 2013 Rachel Nuzum, Vice President Federal & State Policy The Commonwealth Fund A Private Foundation
More informationEstablishment of Clinical Trial Infrastructure
Taiwan s Strategy in the Establishment of Clinical Trial Infrastructure Chei-Hsiang Chen, Ph. D. Director, Biotechnology and Pharmaceutical Industries Program Office, Ministry of Economic Affairs, Taiwan
More informationThe Research Services Organization (RSO) of the Academic Health Center
Annual Report 2005 The Research Services Organization (RSO) of the Academic Health Center A Summary of the Eighth Year of Operations Submitted by: Mark S. Paller, M.D., M.S. Director, Research Services
More informationCalculating the Direct and Indirect Costs of a Phase III HABP/VABP Clinical Study Stella Stergiopoulos Senior Project Manager Tufts CSDD
Calculating the Direct and Indirect Costs of a Phase III HABP/VABP Clinical Study Stella Stergiopoulos Senior Project Manager Tufts CSDD CTTI Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated
More informationSummary of Day 1. Christopher Granger
Summary of Day 1 Christopher Granger 508 million tweets Across the globe 2008 to 2010 Science Sept 30 2011 Selected Points Large simple trials are not so simple, and can also be called large streamlined
More informationApril 13, Background
Pfizer Inc 235 East 42nd Street New York, NY 10017-5755 Tel 212 733 4210 Fax 646 383 9249 Email: marc.wilenzick@pfizer.com April 13, 2009 http://www.regulations.gov Christine Ireland Committee management
More informationHospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee)
Page 1 of 8 Hospital Authority (HA) Guide on Research Ethics (for Study Site & Version Effective Date 2 01/02/2015 Document Number HAHO-CE&TM-HA REC Author HA Head Office Steering Committee on Research
More information1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
More informationClinicalTrials.gov Registration and Results Reporting: Updates and Recent Activity
Vol. 7, No. 2, February 2011 Can You Handle the Truth? ClinicalTrials.gov Registration and Results Reporting: Updates and Recent Activity By Matthew Lester and Barbara Godlew The Food and Drug Administration
More informationExternal IRB Review What Does it Mean for Your Institution
External IRB Review What Does it Mean for Your Institution Wesley G Byerly, Pharm.D. Associate Vice President for Research Integrity and Regulatory Affairs University of Connecticut and UCONN Health HCCA
More informationEthics Committees/IRBs Today: Challenges for Efficiency and Quality
Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationIBM Clinical Trial Management System for Sites
Service Description IBM Clinical Trial Management System for Sites This Service Description describes the Cloud Service IBM provides to Client. Client means the contracting party and its authorized users
More informationHarmonized Core Competencies for the Clinical Research Professional
A collaboration for the harmonization of education and training requirements for clinical research professionals Harmonized Core Competencies for the Clinical Research Professional January 31, 2014 Rebecca
More informationESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL
Assemble Essential Documents in Trial Master File (TMF) Appendix 1 ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.2 Before the Clinical Phase of the Trial Commences During this planning stage
More informationOpportunities and Challenges in Clinical Trials, South Africa. Dr Dorah Diale. South African Health Products Regulatory Authority 27 March 2018
Opportunities and Challenges in Clinical Trials, South Africa Dr Dorah Diale South African Health Products Regulatory Authority 27 March 2018 1 INTRODUCTION (1) Background to Clinical Trials South Africa
More informationTerri Hinkley, RN, BScN, MBA, CCRC Deputy Executive Director, ACRP
INTEGRATION OF THE CORE COMPETENCY FRAMEWORK INTO THE ACRP CAREER DEVELOPMENT PATHWAY, LINKAGE OF EDUCATION AND TRAINING PROGRAMS WITH COMPETENCIES AND NEXT STEPS Terri Hinkley, RN, BScN, MBA, CCRC Deputy
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org December 28, 2010 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationImpact of the Regulatory. Development and Innovation
Impact of the Regulatory Framework on Medical Device Development and Innovation David W Feigal, M.D., M.P.H. Associate Faculty, Sandra Day O Connor School of Law Arizona State University, Tempe Vice President,
More informationAccelerating Clinical Trials Through Access to Real-World Patient Data
Accelerating Clinical Trials Through Access to Real-World Patient Data Accelerating Clinical Trials Through Access to Real-World Patient Data Executive Summary: Leveraging Normalized Real-World Patient
More informationPrimary Care mcta 2013: Guidance for use
GUIDANCE ON USE OF THE MODEL CLINICAL TRIAL AGREEMENT FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY SPONSORED RESEARCH IN PRIMARY CARE (PRIMARY CARE mcta, 2013 VERSION) Background to the development
More informationPOST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)
POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) Purpose: Investigators who initiate and submit an IND application to the FDA assume the responsibilities of both the
More informationThe HMO Research Network
The HMO Research Network Introducing the HMORN The HMO Research Network (HMORN) brings together research departments of some of the U.S. s best and most innovative health care systems. Collectively, the
More informationPROCEDURE OF FILING A REQUEST TO THE ETHICS COMMITEE OF THE UNIVERSITY CLINICAL CENTRE OF THE REPUBLIC OF SRPSKA
PROCEDURE OF FILING A REQUEST TO THE ETHICS COMMITEE OF THE UNIVERSITY CLINICAL CENTRE OF THE REPUBLIC OF SRPSKA All requests, reports and letters to the Ethics Committee of the UCC RS (hereinafter referred
More informationmedicines, improving the health of people around the world.
TransCelerate BioPharma Inc. is a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community to identify, design and facilitate the implementation
More informationFRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up?
FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up? The following framework of characteristics focuses on attributes that are within the control of investigators and their
More informationPOSITION DESCRIPTIONS
Chief Executive Officer Responsible for planning, directing, coordinating and controlling the overall operations of the organization and subsidiaries. Directs short and long-range functions including development
More informationAmerican Society for Investigative Pathology Investigating the Pathogenesis of Disease
American Society for Investigative Pathology Investigating the Pathogenesis of Disease MARK E. SOBEL, MD, PHD EXECUTIVE OFFICER 1801 Rockville Pike, Suite 350, Rockville, MD 20852 (USA) Tel: 240-283-9700
More informationWhat s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance
Vol. 9, No. 2, February 2013 Happy Trials to You What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance Reprinted from the Guide to Good Clinical Practice with permission of Thompson Publishing
More informationAmarex Clinical Research Washington DC metro area A Product Development Services Company. From Lab to Market Approval
Amarex Clinical Research Washington DC metro area A Product Development Services Company Regulatory Strategy From Lab to Market Approval Strategy Implementation Pre-Clinical Assays Global Clinical Trials
More informationOffice Of Clinical Trials. Christine Nelson, RN, BSN, MBA, CCRC
Office Of Clinical Trials Christine Nelson, RN, BSN, MBA, CCRC OCT Mission Statement The mission of the Office of Clinical Trials (OCT) is to serve the Carolina research community by improving the quality
More informationEthics in CTs. The Role of the Regulator versus The Role of the REB
gust 22, 2007 8:45 11:45 gust 22, 2007 8:45 11:45 ADVANCED WORKSHOP : REVIEW OF Helping the people of Canada maintain and improve their health Aider les Canadiens et les Canadiennes à maintenir et à améliorer
More informationTHE FDA, THE DRUG APPROVAL PROCESS, AND THE PATIENT VOICE
THE FDA, THE DRUG APPROVAL PROCESS, AND THE PATIENT VOICE Ali Mohamadi, M.D. Senior Director, Global Regulatory Patient Engagement and Policy BioMarin Pharmaceutical 30-July-2016 Goals of Today s Presentation
More informationThe Yale Open Data Access (YODA) Project: Repurposing Data for Researchers
The Yale Open Data Access (YODA) Project: Repurposing Data for Researchers American Library Association Annual Meeting June 27, 2016 Jessica Ritchie Klein, MPH, PMP YODA Project Manager Center for Outcomes
More informationProtection of Research Participants: The IRB Process and the Winds of Change
Protection of Research Participants: The IRB Process and the Winds of Change Ethics in Patient-Oriented Research October 12, 2011 Sharon Friend Director, OHRPP Overview Charge and Function of the IRB Quick
More informationBipartisan Policy Center, Top Medical Innovation Priorities
Bipartisan Policy Center, Top Medical Priorities FDA: Advancing Medical is a Bipartisan Policy Center initiative led by former Senator Bill Frist, MD, former Congressman Bart Gordon, and BPC Health Initiative
More informationQuality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework
1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health
More informationand Study Initiation
10 STUDY SPECIFIC PRE-IMPLEMENTATION, SITE ACTIVATION AND STUDY INITIATION... 2 10.1 Clinical Trials Agreement... 4 10.2 Study Product Acquisition and Shipment to Sites... 5 10.3 Study-specific Preparatory,
More informationand Study Initiation
10 STUDY SPECIFIC PRE-IMPLEMENTATION, SITE ACTIVATION AND STUDY INITIATION... 2 10.1 Clinical Trials Agreement... 4 10.2 Study Product Acquisition and Shipment to Sites... 5 10.3 Study-specific Preparatory,
More informationPrecision Medicine: Harnessing Biomedical Data to Improve the Prediction, Prevention, Diagnosis and Treatment of Disease
Precision Medicine: Harnessing Biomedical Data to Improve the Prediction, Prevention, Diagnosis and Treatment of Disease Session #61, February 20, 2017 Jason Levine, MD, Assoc. Director of Clinical Informatics,
More informationAgenda: Opportunities in Developing Orphan Drug Products. Mukesh Kumar, PhD, RAC
This Seminar is Brought to you by Amarex Clinical Research Washington DC metro area A Product Development Services Company From Lab to Market Approval FDA Meetings Global Regulatory Submissions Global
More informationYale University. Open Data Access Project
Open Data Access Project A Model for Dissemination and Independent Analysis of Clinical Trial Program Data Funded by a contract with Medtronic, Inc. Rationale A substantial number of clinical trials are
More informationThe Yale Open Data Access (YODA) Project: Lessons Learned in Data Sharing
The Yale Open Data Access (YODA) Project: Lessons Learned in Data Sharing Grand Rounds: A Shared Forum of the NIH HCS Collaboratory and PCORnet June 30, 2017 Joseph S. Ross, MD, MHS Section of General
More informationIssues in Cancer Drug Development of the Future. Janet Woodcock M.D. Deputy Commissioner/Chief Medical Officer, FDA October 5, 2007
Issues in Cancer Drug Development of the Future Janet Woodcock M.D. Deputy Commissioner/Chief Medical Officer, FDA October 5, 2007 Agenda: Scientific Issues n Why improve the quality of cancer clinical
More informationMay 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers
More informationResearch Job Summaries
Job Summaries Job 32713 32712 32711 32613 32612 32611 32516 32515 32514 32513 32512 32511 Chief Officer Deputy Chief Officer Senior Officer Officer The Chief Officer (CRO) serves as an integral member
More informationRUTGERS IJOBS WORKSHOP REGULATORY WRITING JANUARY 30, 2018
1 RUTGERS IJOBS WORKSHOP REGULATORY WRITING JANUARY 30, 2018 Doreen W Lechner, PhD Program Director, MS Clinical Trial Sciences Program Biopharma Educational Initiative Rutgers School of Health Professions
More informationREGULATORY REQUIREMENTS FOR CLINICAL TRIAL APPROVAL MEDICAL DEVICES DR D DIALE MRS P NKAMBULE. 02 December 2015
REGULATORY REQUIREMENTS FOR CLINICAL TRIAL APPROVAL MEDICAL DEVICES DR D DIALE MRS P NKAMBULE 02 December 2015 LAYOUT Background to clinical trials Stakeholders in clinical trials Legislative requirements
More informationTHE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices
More informationIRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010
IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized
More informationRegulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1
Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1 Phone: 650.691.4400 Fax: 650.691.4410 Email: regulatory.ccsainc.com COMPLIANCE & STANDARDIZATION Rationale for Revision of
More information5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)
5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) GCP Requirements and Compliance Dr. Katalina Mettke BfArM, Germany Agenda Specialities of Early Development Trials Examples
More informationRe: Docket No. 2006D-0347, Federal Register: July 26, 2007 (Volume 72, Pages )
1201 Maryland Avenue SW, Ste. 900 Washington, DC 20024 August 27, 2007 BY ELECTRONIC DELIVERY Division of Dockets Management (HFA-305) Food and Drug Administration 56350 Fishers Lane Room 1061 Rockville,
More informationResearch 101. Health Care Compliance Association Regional Conference Columbus, Ohio May 8, 2015
Research 101 Health Care Compliance Association Regional Conference Columbus, Ohio May 8, 2015 Jennifer Lanter, MSPH, BSN, RN, CCRC Director, Research & Special Billing Office Agenda Research Compliance
More informationYour complimentary Clinica Medtech Intelligence content
Your complimentary Clinica Medtech Intelligence content Clinica provides you with up to the minute coverage and opinion on company, product, market and regulatory developments as well as market size, growth
More informationCDER Perspective: Challenges in Clinical Trials and the Path Forward
CDER Perspective: Challenges in Clinical Trials and the Path Forward Pharmaceutical Compliance Congress and Best Practices Forum November 3, 2011 Ann Meeker O Connell, MS, CCEP Associate Director (Acting),
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org June 19, 2008 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationStem Cell Research: Identifying emerging high priority policy issues
The state stem cell agency Stem Cell Research: Identifying emerging high priority policy issues Ellen G. Feigal, M.D. SVP, Research and Development National Cancer Policy Summit Washington, DC November
More informationConducting Clinical Trials of Investigational Medicinal Products
Title: Outcome Statement: Written By: Reviewed By: Conducting Clinical Trials of Investigational Medicinal Products Researchers in the Trust and research partners will be informed about the procedures
More informationYale University. Open Data Access Project
Open Data Access Project A Model for Dissemination and Independent Analysis of Clinical Trial Program Data Funded by a contract with Medtronic, Inc. Session Objectives Why do we need to promote data sharing?
More informationSTANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File
Research Department STANDARD OPERATING PROCEDURE STH Researcher SOP History CSUH 00/016 SOP Number A116 Created STH Research Department (TL) Reviewed by STH Research Department (AL) 06 August 2009 Superseded
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationWelcome to Demystifying the Executive Search Process
Welcome to Demystifying the Executive Search Process We will begin the seminar at 12:10 p.m. ET No cameras today Please mute your audio Virtual Seminar archive: http://myhcds.dartmouth.edu #mhcdslive Upcoming
More informationPolicy Appendix IV: DRCR.net Industry Collaboration Policies Version 5.0, February 2, 2009
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 DRCR.net is committed to: performing rigorous multi-center clinical
More informationBO STO N MEDTECH. More Experience Better Results. Ethics in Clinical Research. Zvi Ladin, Ph.D.
BO STO N MEDTECH A D VI SO RS More Experience Better Results Ethics in Clinical Research Zvi Ladin, Ph.D. Historical Infamy Tuskegee syphilis study (1930s 1972) 399 black men signed with the US PHS for
More informationGood Clinical Practice (GCP) & Clinical Trial Registries
Good Clinical Practice (GCP) & Clinical Trial Registries The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practice Forum November 14-17, 2004 Kate Maloney, RN, MS, CPHQ Manager,
More informationWRITTEN SUBMISSION ON THE OPERATION OF THE CLINICAL TRIALS DIRECTIVE (DIRECTIVE 2001/20/EC) AND PERSPECTIVES FOR THE FUTURE
WRITTEN SUBMISSION ON THE OPERATION OF THE CLINICAL TRIALS DIRECTIVE (DIRECTIVE 2001/20/EC) AND PERSPECTIVES FOR THE FUTURE ECRIN (European Clinical Research Infrastructures Network) EORTC (European Organization
More informationGUIDELINES FOR CONDUCTING CLINICAL TRIALS.
GUIDELINES FOR CONDUCTING CLINICAL TRIALS. FOREWORD The purpose of Drug Registration is to ensure that a pharmaceutical product has been adequately tested and evaluated for safety, efficacy and quality,
More informationSIAPS assistance is grouped into four technical areas
Our specific approaches to each of the five result areas follows Governance Under SIAPS, our approach to improving governance and accountability focuses on establishing transparent management systems grounded
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
POLICY #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional
More informationPolicy Appendix IV: DRCR.net Industry Collaboration Policies Version 6.0, August 2, 2017
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 DRCR.net is committed to: performing rigorous multi-center clinical
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationTrends in Oversight of Human Research Protections?
Trends in Oversight of Human Research Protections? Greg Koski, PhD, MD Associate Professor, Harvard Medical School Senior Scientist, James Mongan Institute for Health Policy Former Director, Office for
More informationORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS
ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS 2018-2024 ORACLE 2.0: Leading Globally, from Innovation to Impact P1 P2 NOTE FROM OUR LEADERS NOTE FROM VP RESEARCH,
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities
More informationAPEC GCP Inspection Workshop May 29, 2008
Common Investigator Deficiencies Jean Toth-Allen, Ph.D. APEC GCP Inspection Workshop May 29, 2008 Most Common CI Deficiencies Failure to follow the investigational plan Protocol deviations Inadequate recordkeeping
More information